HBV

Future Planet invests in Vaccitech's $168M Series B

London, UK – 17th March 2021: Future Planet Capital has invested in a $168m Series B financing announced today by Vaccitech Ltd.  Future Planet joins other leading investors including M&G Investment Management, Tencent, Gilead Sciences, Monaco Constitutional Reserve Fund and fellow existing investor, Oxford Sciences Innovation. As part of the Series B financing, $43 million in convertible loan notes previously issued by Vaccitech will convert into Series B shares, resulting in total gross proceeds to Vaccitech of $168 million before expenses.

Douglas Hansen-Luke Founder & EXec Chair Future Planet Capital

Douglas Hansen-Luke Founder & EXec Chair

Future Planet Capital

Douglas Hansen-Luke, Executive Chairman of Future Planet Capital, explained:

"Our decision to support Vaccitech last year, before the results of the COVID-19 Vaccine AstraZeneca trials were known, has been vindicated by the vaccine’s approval for emergency use by national and international regulators. The success of the COVID-19 Vaccine AstraZeneca has increased our confidence in Vaccitech’s immunotherapy platform and our continuing support is signalled by our investment today.”

Bill Enright, CEOVaccitech

Bill Enright, CEO

Vaccitech

Bill Enright, CEO of Vaccitech, said:

“We expect this financing to enable us to reach key value inflection points for our lead programs. We now look forward to advancing key programs towards generating proof-of-concept data in indications with significant need of effective new treatments.”

Ed Phillips, Deal Lead Future Planet Capital

Ed Phillips, Deal Lead

Future Planet Capital

Ed Phillips, Head of Origination at Future Planet Capital, concluded:

“This is a concrete example of our vision in action – financing the best minds to address global challenges. We look forward to working with other entrepreneurs and businesses dedicated to solving global challenges in the future.”

Vaccitech is a clinical stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer; in 2020 it co-invented a COVID-19 vaccine candidate with the University of Oxford, AZD1222, which is known as the COVID-19 Vaccine AstraZeneca.

-ends-

For further information, please contact;

Future Planet Capital: Ed Philips, Head of Origination: e.phillips@futureplanetcapital.com

Sciad Communications: Richard Anderson: richard@sciad.com, Emma Pickup: emma@sciad.com

Screenshot+2021-03-16+at+17.42.09.jpg